Abstract
Lee and colleagues report that increase in serum cholesterol is associated with improved clinical outcomes in patients with renal cell carcinoma treated with temsirolimus. Although these findings must be validated prospectively, it should also be determined if this marker is a true mechanism-based toxicity or an epiphenomenon associated with therapy.
Publication types
-
Research Support, N.I.H., Extramural
-
Comment
MeSH terms
-
Antineoplastic Agents / therapeutic use*
-
Carcinoma, Renal Cell / blood*
-
Carcinoma, Renal Cell / drug therapy*
-
Cholesterol / blood*
-
Female
-
Humans
-
Kidney Neoplasms / blood*
-
Kidney Neoplasms / drug therapy*
-
Male
-
Sirolimus / analogs & derivatives*
-
Sirolimus / therapeutic use
Substances
-
Antineoplastic Agents
-
temsirolimus
-
Cholesterol
-
Sirolimus